References
- Spiteri G, Fielding J, Diercke M, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9). doi:10.2807/1560-7917.ES.2020.25.9.2000178.
- Nicola M, O’Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic - Review article. Int J Surg. 2020;77:206–216. doi:10.1016/j.ijsu.2020.04.00132289472
- Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76. doi:10.1016/j.ijsu.2020.02.03432112977
- Coronavirus Cases; 2020 Available from: https://www.worldometers.info/coronavirus/. Accessed 312, 2020.
- Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of Coronavirus (COVID-19) In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
- Fagbule OF. 2019 Novel Coronavirus. Ann Ib Postgrad Med. 2019;17(2):108–110.32669985
- Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020;94:44–48. doi:10.1016/j.ijid.2020.03.00432171952
- Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020;16(10):1686–1697. doi:10.7150/ijbs.4547232226286
- Karia R, Gupta I, Khandait H, Yadav A, Yadav A. COVID-19 and its Modes of Transmission. SN Compr Clin Med. 2020;1–4.
- Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765. doi:10.1371/journal.pone.023476532574165
- Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35.32232218
- Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020;12(10):9959–9981. doi:10.18632/aging.10334432470948
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
- Deshmukh SK, Tyagi N, Khan MA, et al. Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. Sci Rep. 2018;8(1):12000. doi:10.1038/s41598-018-30437-230097594
- Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284. doi:10.1101/gad.314617.11830275043
- Kalathil SG, Thanavala Y. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. Cancer Immunol Immunother. 2016;65(7):813–819. doi:10.1007/s00262-016-1810-026910314
- Ballard M, Bancroft E, Nesbit J, et al. Prioritising the role of community health workers in the COVID-19 response. BMJ Glob Health. 2020;5(6):e002550. doi:10.1136/bmjgh-2020-002550
- Barach P, Fisher SD, Adams MJ, et al. Disruption of healthcare: will the COVID pandemic worsen non-COVID outcomes and disease outbreaks? Prog Pediatr Cardiol. 2020;59:101254. doi:10.1016/j.ppedcard.2020.10125432837144
- Perrone AM, De Palma A, De Iaco P. COVID-19 global pandemic: options for management of gynecologic cancers. The experience in surgical management of ovarian cancer in the second highest affected Italian region. Int J Gynecol Cancer. 2020;30(6):902. doi:10.1136/ijgc-2020-00148932381511
- Chu KM, Smith M, Steyn E, Goldberg P, Bougard H, Buccimazza I. Changes in surgical practice in 85 South African hospitals during COVID-19 hard lockdown. S Afr Med J. 2020;110(9):916–919.32880278
- Kumar D, Dey T. Treatment delays in oncology patients during COVID-19 pandemic: a perspective. J Glob Health. 2020;10(1):010367. doi:10.7189/jogh.10.01036732566158
- Sharma DC. Lockdown poses new challenges for cancer care in India. Lancet Oncol. 2020;21(7):884. doi:10.1016/S1470-2045(20)30312-032479789
- Tisdell CA. Economic, social and political issues raised by the COVID-19 pandemic. Econ Anal Policy. 2020;68:17–28. doi:10.1016/j.eap.2020.08.00232843816
- Chudasama YV, Gillies CL, Zaccardi F, et al. Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab Syndr. 2020;14(5):965–967. doi:10.1016/j.dsx.2020.06.04232604016
- Gopalan HS, Misra A. COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India. Diabetes Metab Syndr. 2020;14(5):757–759. doi:10.1016/j.dsx.2020.05.04132504992
- Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020;78:185–193. doi:10.1016/j.ijsu.2020.04.01832305533
- Das PM, Bast Jr RC. Early detection of ovarian cancer. Biomark Med. 2008;2(3):291–303. doi:10.2217/17520363.2.3.29120477415
- Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.2145629809280
- Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93(11):937–944.27281838
- Chien J, Poole EM. Ovarian cancer prevention, screening, and early detection: report from the 11th biennial ovarian cancer research symposium. Int J Gynecol Cancer. 2017;27(Suppl 9):S20–S22. doi:10.1097/IGC.000000000000111829278600
- Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018–7031. doi:10.1002/cam4.256031560828
- Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38. doi:10.1007/s00280-017-3501-829249039
- Indini A, Rijavec E, Ghidini M, Cattaneo M, Grossi F. Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. Eur J Cancer. 2020;135:47–50. doi:10.1016/j.ejca.2020.05.01732534244
- Indini A, Aschele C, Cavanna L, et al. Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. Eur J Cancer. 2020;132:17–23. doi:10.1016/j.ejca.2020.03.02432311643
- Ramirez PT, Chiva L, Eriksson AGZ, et al. COVID-19 global pandemic: options for management of gynecologic cancers. Int J Gynecol Cancer. 2020;30(5):561–563. doi:10.1136/ijgc-2020-00141932221023
- Greer BE, Swensen RE, Gray HJ. Surgery for ovarian cancer: rationale and guidelines. J Natl Compr Canc Netw. 2004;2(6):561–568. doi:10.6004/jnccn.2004.004719780300
- Smith CG, Davenport DL, Gorski J, et al. Clinical factors associated with longer hospital stay following ovarian cancer surgery. Healthcare (Basel). 2019;7(3). doi:10.3390/healthcare7030085.
- Stewart JM, Tone AA, Jiang H, et al. The optimal time for surgery in women with serous ovarian cancer. Can J Surg. 2016;59(4):223–232. doi:10.1503/cjs.01431527240134
- Al-Jabir A, Kerwan A, Nicola M, et al. Impact of the Coronavirus (COVID-19) pandemic on surgical practice - Part 2 (surgical prioritisation). Int J Surg. 2020;79:233–248. doi:10.1016/j.ijsu.2020.05.00232413502
- Al-Jabir A, Kerwan A, Nicola M, et al. Impact of the Coronavirus (COVID-19) pandemic on surgical practice - Part 1. Int J Surg. 2020;79:168–179. doi:10.1016/j.ijsu.2020.05.02232407799
- Voices of women with ovarian cancer: the coronavirus pandemic and its impact; 2020 Available from: https://targetovariancancer.org.uk/sites/default/files/2020-07/Voices%20of%20women%20with%20ovarian%20cancer%20-%20the%20coronavirus%20pandemic%20and%20its%20impact.pdf. Accessed 2020.
- Frey MK, Ellis AE, Zeligs K, et al. Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. Am J Obstet Gynecol. 2020;223:725.e1–725.e9. doi:10.1016/j.ajog.2020.06.049
- Bogani G, Raspagliesi F. Minimally invasive surgery at the time of COVID-19: the OR staff needs protection. J Minim Invasive Gynecol. 2020;27(5):1221. doi:10.1016/j.jmig.2020.04.010
- Bogani G, Apolone G, Ditto A, et al. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. J Gynecol Oncol. 2020;31(6):e92. doi:10.3802/jgo.2020.31.e9233078597
- Nakayama J, El-Nashar SA, Waggoner S, Traughber B, Kesterson J. Adjusting to the new reality: evaluation of early practice pattern adaptations to the COVID-19 pandemic. Gynecol Oncol. 2020;158(2):256–261. doi:10.1016/j.ygyno.2020.05.02832482336
- Indini A, Rijavec E, Ghidini M, et al. Coronavirus infection and immune system: an insight of COVID-19 in cancer patients. Crit Rev Oncol Hematol. 2020;153:103059. doi:10.1016/j.critrevonc.2020.10305932711241
- Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020;21:100331. doi:10.1016/j.eclinm.2020.10033132292899
- Liu Y, Song Y, Hu X, Yan L, Zhu X. Awareness of surgical smoke hazards and enhancement of surgical smoke prevention among the gynecologists. J Cancer. 2019;10(12):2788–2799. doi:10.7150/jca.3146431258787
- Mowbray NG, Ansell J, Horwood J, et al. Safe management of surgical smoke in the age of COVID-19. Br J Surg. 2020. doi:10.1002/bjs.11679
- Bogani G, Casarin J, Pinelli C, et al. Management of patients with ovarian cancer in the COVID-19 era. J Surg Oncol. 2020;122(2):122–123. doi:10.1002/jso.2605732476155
- Bogani G, Signorelli M, Ditto A, Raspagliesi F. Surgical oncology at the time of COVID-19 outbreak. J Surg Oncol. 2020;122(2):115–116. doi:10.1002/jso.2597532497294
- Cooney E We have a job to do’: cancer patients and their doctors carry on with clinical trials during Covid-19; 2020 Available from: https://www.statnews.com/2020/06/16/cancer-patients-doctors-carry-on-clinical-trials-during-covid-19/. Accessed 2020.
- Crawford A, Haber L, Kelly MP, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019;11:497. doi:10.1126/scitranslmed.aau7534
- Kent DG, Knapp D, Kannan N. Survey says: “COVID-19 lockdown hits young faculty and clinical trials. Stem Cell Rep. 2020;15(1):1–5. doi:10.1016/j.stemcr.2020.06.010
- Monk BJ, Coleman RL, Moore KN, et al. COVID-19 and ovarian cancer: exploring alternatives to intravenous (IV) therapies. Gynecol Oncol. 2020;158(1):34–36. doi:10.1016/j.ygyno.2020.04.70332370991
- Nassisi M, Audo I, Zeitz C, et al. Impact of the COVID-19 lockdown on basic science research in ophthalmology: the experience of a highly specialized research facility in France. Eye (Lond). 2020;34(7):1187–1188. doi:10.1038/s41433-020-0944-732382143
- Rolston KV. Infections in cancer patients with solid tumors: a review. Infect Dis Ther. 2017;6(1):69–83. doi:10.1007/s40121-017-0146-128160269
- Rusu RA, Sirbu D, Curseu D, et al. Chemotherapy-related infectious complications in patients with Hematologic malignancies. J Res Med Sci. 2018;23:68. doi:10.4103/jrms.JRMS_960_1730181750
- Walsh CS. Latest clinical evidence of maintenance therapy in ovarian cancer. Curr Opin Obstet Gynecol. 2020;32(1):15–21. doi:10.1097/GCO.000000000000059231833941
- Penson RT, Valencia RV, Cibula D, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38(11):1164–1174. doi:10.1200/JCO.19.0274532073956
- Transforming futures for women with ovarian cancer. Available from: https://targetovariancancer.org.uk/sites/default/files/2020-07/Pathfinder%202016%20-%20Wales%20report%20%28English%29.pdf. 2020 Accessed 2020.